BioCryst Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2009 |
|---|---|
| Revenue | $74.6M |
| Cost of Revenue | $4.5M |
| Gross Profit | $70.0M |
| Gross Margin | 93.9% |
| Operating Expenses | |
| Research & Development | $73.7M |
| SG&A Expense | $10.1M |
| Operating Income | $-13.7M |
| Operating Margin | -18.4% |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-13.5M |
| Net Margin | -18.0% |
| EPS (Basic) | $-0.35 |
| EPS (Diluted) | $-0.35 |
| Shares Outstanding (Basic) | — |
| Shares Outstanding (Diluted) | — |
| Dividends Per Share | — |